Oesophageal cancer

The Lancet

Volumn 390, Issue 10110, 2017, Pages 2383-2396

  Lagergren, Jesper ^a,b   Smyth, Elizabeth ^c   Cunningham, David ^c   Lagergren, Pernilla ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COCHRANE LIBRARY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; LOCAL THERAPY; LYMPH NODE DISSECTION; MEDLINE; NEOADJUVANT CHEMOTHERAPY; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; AGED; DISEASE FREE SURVIVAL; ESOPHAGOSCOPY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85021212659     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31462-9     Document Type: Review

References (159)

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C, Dicker, D, et al. The Global Burden of Cancer 2013. JAMA Oncol 1 (2015), 505–527.
2. Jacobs, M, Macefield, RC, Elbers, RG, et al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. Qual Life Res of 23 (2014), 1097–1115.
3. Edgren, G, Adami, HO, Weiderpass, E, Nyren, O, A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62 (2013), 1406–1414.
4. Xie, SH, Lagergren, J, A global assessment of the male predominance in esophageal adenocarcinoma. Oncotarget 7 (2016), 38876–38883.
5. Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
6. Arnold, M, Soerjomataram, I, Ferlay, J, Forman, D, Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64 (2015), 381–387.
7. Edgren, G, Adami, HO, Weiderpass Vainio, E, Nyren, O, A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62 (2013), 1406–1414.
8. Gavin, AT, Francisci, S, Foschi, R, et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol 36 (2012), 505–512.
9. Njei, B, McCarty, TR, Birk, JW, Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol 31 (2016), 1141–1146.
10. Zeng, H, Zheng, R, Guo, Y, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer 136 (2015), 1921–1930.
11. Chau, I, Norman, AR, Cunningham, D, Waters, JS, Oates, J, Ross, PJ, Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22 (2004), 2395–2403.
12. Prabhu, A, Obi, KO, Rubenstein, JH, The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol 109 (2014), 822–827.
13. Liu, J, Wang, J, Leng, Y, Lv, C, Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer 133 (2013), 473–485.
14. Qu, X, Ben, Q, Jiang, Y, Consumption of red and processed meat and risk for esophageal squamous cell carcinoma based on a meta-analysis. Ann Epidemiol 23 (2013), 762–770.
15. Chen, Y, Tong, Y, Yang, C, et al. Consumption of hot beverages and foods and the risk of esophageal cancer: a meta-analysis of observational studies. BMC Cancer, 15, 2015, 449.
16. Wu, C, Wang, Z, Song, X, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 46 (2014), 1001–1006.
17. Bosetti, C, Gallus, S, Garavello, W, La Vecchia, C, Smoking cessation and the risk of oesophageal cancer: an overview of published studies. Oral Oncol 42 (2006), 957–964.
18. Spechler, SJ, Souza, RF, Barrett's esophagus. N Engl J Med 371 (2014), 836–845.
19. Lagergren, J, Lagergren, P, Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 63 (2013), 232–248.
20. Buas, MF, He, Q, Johnson, LG, et al. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2016, 10.1136/gutjnl-2016-311622 published online Aug 2.
21. Ek, WE, Lagergren, K, Cook, M, et al. Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 138 (2016), 1146–1152.
22. Lagergren, K, Ek, WE, Levine, D, et al. Polymorphisms in genes of relevance for oestrogen and oxytocin pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. PLoS One, 10, 2015, e0138738.
23. Gharahkhani, P, Fitzgerald, RC, Vaughan, TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol 17 (2016), 1363–1373.
24. Maret-Ouda, J, El-Serag, HB, Lagergren, J, Opportunities for preventing esophageal adenocarcinoma. Cancer Prev Res 9 (2016), 828–834.
25. Cancer Genome Atlas Research Network Analysis Working Group, Asan University. Integrated genomic characterization of oesophageal carcinoma. Nature 541 (2017), 169–175 et al.
26. Lagergren, J, Lagergren, P, Oesophageal cancer. BMJ, 341, 2010, c6280.
27. Secrier, M, Li, X, de Silva, N, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48 (2016), 1131–1141.
28. Brierley, JD, Gospodarowicz, MK, Wittekind, C, TNM classification of malignant tumours, 8th edn., 2016, Wiley-Blackwell, Hoboken.
29. Siewert, JR, Stein, HJ, Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998), 1457–1459.
30. Findlay, JM, Bradley, KM, Maile, EJ, et al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. Br J Surg 102 (2015), 1488–1499.
31. Chadwick, G, Riley, S, Hardwick, RH, et al. Population-based cohort study of the management and survival of patients with early-stage oesophageal adenocarcinoma in England. Br J Surg 103 (2016), 544–552.
32. Allum, WH, Blazeby, JM, Griffin, SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 60 (2011), 1449–1472.
33. Carney, A, Dickinson, M, Anesthesia for esophagectomy. Anesthesiol Clin 33 (2015), 143–163.
34. Wright, CD, Kucharczuk, JC, O'Brien, SM, Grab, JD, Allen, MS, for the Society of Thoracic Surgeons General Thoracic Surgery Database. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg 137 (2009), 587–595.
35. Yoshida, N, Baba, Y, Shigaki, H, et al. Preoperative nutritional assessment by controlling nutritional status (CONUT) is useful to estimate postoperative morbidity after esophagectomy for esophageal Cancer. World J Surg 40 (2016), 1910–1917.
36. Djarv, T, Metcalfe, C, Avery, KN, Lagergren, P, Blazeby, JM, Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. J Clin Oncol 28 (2010), 1666–1670.
37. Kidane, B, Sulman, J, Xu, W, et al. Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status. Eur J Cardiothorac 51 (2016), 148–154.
38. Le Roy, B, Pereira, B, Bouteloup, C, et al. Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial-the PREHAB study. BMJ Open, 6, 2016, e012876.
39. Lordick, F, Mariette, C, Haustermans, K, Obermannova, R, Arnold, D, for the ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:suppl 5 (2016), 50–57.
40. van Hagen, P, Spaander, MC, van der Gaast, A, et al. Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol 18 (2013), 214–219.
41. Schmidt, HM, Roberts, JM, Bodnar, AM, et al. Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study. Ann Thorac Surg 99 (2015), 1719–1724.
42. Boniface, MM, Wani, SB, Schefter, TE, et al. Multidisciplinary management for esophageal and gastric cancer. Cancer Manag Res 8 (2016), 39–44.
43. Merkow, RP, Bilimoria, KY, Keswani, RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst, 2014, 10.1093/jnci/dju133 published online July 16.
44. Shaheen, NJ, Sharma, P, Overholt, BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360 (2009), 2277–2288.
45. He, S, Bergman, J, Zhang, Y, et al. Endoscopic radiofrequency ablation for early esophageal squamous cell neoplasia: report of safety and effectiveness from a large prospective trial. Endoscopy 47 (2015), 398–408.
46. Bergman, JJ, Zhang, YM, He, S, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc 74 (2011), 1181–1190.
47. Phoa, KN, van Vilsteren, FG, Weusten, BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 311 (2014), 1209–1217.
48. Hu, Y, Puri, V, Shami, VM, Stukenborg, GJ, Kozower, BD, Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg 263 (2016), 719–726.
49. Haidry, RJ, Butt, MA, Dunn, JM, et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 64 (2015), 1192–1199.
50. Neuhaus, H, Terheggen, G, Rutz, EM, Vieth, M, Schumacher, B, Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus. Endoscopy 44 (2012), 1105–1113.
51. Sun, F, Yuan, P, Chen, T, Hu, J, Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta-analysis. J Cardiothorac Surg, 9, 2014, 78.
52. Guo, HM, Zhang, XQ, Chen, M, Huang, SL, Zou, XP, Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol 20 (2014), 5540–5547.
53. Wu, J, Pan, YM, Wang, TT, Gao, DJ, Hu, B, Endotherapy versus surgery for early neoplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc 79 (2014), 233–241.
54. Pasricha, S, Cotton, C, Hathorn, KE, et al. Effects of the learning curve on efficacy of radiofrequency ablation for Barrett's esophagus. Gastroenterology 149 (2015), 890–896.
55. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002), 1727–1733.
56. Allum, WH, Stenning, SP, Bancewicz, J, Clark, PI, Langley, RE, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27 (2009), 5062–5067.
57. Cunningham, D, Allum, WH, Stenning, SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006), 11–20.
58. Ychou, M, Boige, V, Pignon, JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29 (2011), 1715–1721.
59. Al-Batran SE, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. American Society of Clinical Oncology Annual Meeting; Chicago, IL; June 2–June 6, 2017. 4004.
60. van Hagen, P, Hulshof, MC, van Lanschot, JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366 (2012), 2074–2084.
61. Shapiro, J, van Lanschot, JJ, Hulshof, MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16 (2015), 1090–1098.
62. Sjoquist, KM, Burmeister, BH, Smithers, BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12 (2011), 681–692.
63. Mariette, C, Dahan, L, Mornex, F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 32 (2014), 2416–2422.
64. Mariette, C, Gronnier, C, Duhamel, A, et al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. J Am Coll Surg 220 (2015), 287–296.
65. Stahl, M, Stuschke, M, Lehmann, N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005), 2310–2317.
66. Bedenne, L, Michel, P, Bouche, O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 (2007), 1160–1168.
67. Markar, S, Gronnier, C, Duhamel, A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?. J Clin Oncol 33 (2015), 3866–3873.
68. Alderson D, Langley R, Nankivell M, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). ASCO Annual Meeting; Chicago, IL; May 29–June 2, 2015. 4002.
69. Ott, K, Fink, U, Becker, K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 (2003), 4604–4610.
70. Lordick, F, Ott, K, Krause, BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 (2007), 797–805.
71. Ott, K, Weber, WA, Lordick, F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006), 4692–4698.
72. Walsh, TN, Noonan, N, Hollywood, D, Kelly, A, Keeling, N, Hennessy, TP, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996), 462–467.
73. Conroy, T, Galais, MP, Raoul, JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15 (2014), 305–314.
74. Van Laethem, JL, Carneiro, F, Ducreux, M, et al. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis 48 (2016), 1283–1289.
75. Klevebro, F, Alexandersson von Dobeln, G, Wang, N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27 (2016), 660–667.
76. Stahl, M, Walz, MK, Stuschke, M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27 (2009), 851–856.
77. Herskovic, A, Martz, K, al-Sarraf, M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992), 1593–1598.
78. Minsky, BD, Pajak, TF, Ginsberg, RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002), 1167–1174.
79. No authors listedDose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in laryngeal and hypopharyngeal cancer patients. http://www.isrctn.com/ISRCTN01483375, 2017 (accessed May 26, 2017).
80. Pasquali, S, Yim, G, Vohra, RS, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 265 (2016), 481–491.
81. Markar, SR, Gronnier, C, Duhamel, A, et al. Significance of microscopically incomplete resection margin after esophagectomy for esophageal cancer. Ann Surg 263 (2016), 712–718.
82. Chan, DS, Reid, TD, Howell, I, Lewis, WG, Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg 100 (2013), 456–464.
83. Lagarde, SM, Vrouenraets, BC, Stassen, LP, van Lanschot, JJ, Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg 89 (2010), 1319–1326.
84. Zhou, C, Zhang, L, Wang, H, et al. Superiority of minimally invasive oesophagectomy in reducing in-hospital mortality of patients with resectable oesophageal cancer: a meta-analysis. PLoS One, 10, 2015, e0132889.
85. Yerokun, BA, Sun, Z, Jeffrey Yang, CF, et al. Minimally invasive versus open esophagectomy for esophageal cancer: a population-based analysis. Ann Thorac Surg 102 (2016), 416–423.
86. No authors listedROMIO feasibility: randomised controlled trial of minimally invasive or open oesophagectomy. http://www.isrctn.com/ISRCTN59036820, 2017 (accessed March 5, 2017).
87. Biere, SS, van Berge Henegouwen, MI, Maas, KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379 (2012), 1887–1892.
88. Briez, N, Piessen, G, Torres, F, Lebuffe, G, Triboulet, JP, Mariette, C, Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg 99 (2012), 1547–1553.
89. Davies, AR, Sandhu, H, Pillai, A, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg 101 (2014), 511–517.
90. Hulscher, JB, van Sandick, JW, de Boer, AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 (2002), 1662–1669.
91. Markar, SR, Wiggins, T, Ni, M, et al. Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncol 16 (2015), e23–e31.
92. Markar, SR, Mackenzie, H, Lagergren, P, Hanna, GB, Lagergren, J, Surgical proficiency gain and survival after esophagectomy for cancer. J Clin Oncol 34 (2016), 1528–1536.
93. Brusselaers, N, Mattsson, F, Lagergren, J, Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 63 (2014), 1393–1400.
94. Derogar, M, Sadr-Azodi, O, Johar, A, Lagergren, P, Lagergren, J, Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol 31 (2013), 551–557.
95. Rizk, NP, Ishwaran, H, Rice, TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg 251 (2010), 46–50.
96. van der Schaaf, M, Johar, A, Wijnhoven, B, Lagergren, P, Lagergren, J, Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst, 2015, 10.1093/jnci/djv043 published online March 5.
97. Lagergren, J, Mattsson, F, Zylstra, J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg 151 (2015), 32–39.
98. Phillips, AW, Lagarde, SM, Navidi, M, Disep, B, Griffin, SM, Impact of extent of lymphadenectomy on survival, post neoadjuvant chemotherapy and transthoracic esophagectomy. Ann Surg 265 (2016), 750–756.
99. Anderegg, MC, Lagarde, SM, Jagadesham, VP, et al. Prognostic significance of the location of lymph node metastases in patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Ann Surg 264 (2016), 847–853.
100. Schandl, A, Johar, A, Lagergren, J, Lagergren, P, Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study. BMJ Open, 6, 2016, e012624.
101. Jacobs, M, Macefield, RC, Elbers, RG, et al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. Qual Life Res 23 (2014), 1155–1176.
102. Wikman, A, Ljung, R, Johar, A, Hellstadius, Y, Lagergren, J, Lagergren, P, Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol 33 (2015), 448–454.
103. Djarv, T, Blazeby, JM, Lagergren, P, Predictors of postoperative quality of life after esophagectomy for cancer. J Clin Oncol 27 (2009), 1963–1968.
104. Sunde, B, Ericson, J, Kumagai, K, et al. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction. Dis Esophagus 29 (2016), 442–447.
105. Cools-Lartigue, J, Jones, D, Spicer, J, et al. Management of dysphagia in esophageal adenocarcinoma patients undergoing neoadjuvant chemotherapy: can invasive tube feeding be avoided?. Ann Surg Oncol 22 (2015), 1858–1865.
106. Blazeby, JM, Sanford, E, Falk, SJ, Alderson, D, Donovan, JL, Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 103 (2005), 1791–1799.
107. Hauser, C, Patett, C, von Schoenfels, W, et al. Does neoadjuvant treatment before oncologic esophagectomy affect the postoperative quality of life? A prospective, longitudinal outcome study. Dis Esophagus 28 (2015), 652–659.
108. Rees, J, Hurt, CN, Gollins, S, et al. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 113 (2015), 603–610.
109. van der Schaaf, M, Rutegard, M, Lagergren, P, The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden. Ann Surg Oncol 20 (2013), 1639–1645.
110. Rutegard, M, Lagergren, J, Rouvelas, I, Lindblad, M, Blazeby, JM, Lagergren, P, Population-based study of surgical factors in relation to health-related quality of life after oesophageal cancer resection. Br J Surg 95 (2008), 592–601.
111. Derogar, M, Orsini, N, Sadr-Azodi, O, Lagergren, P, Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol 30 (2012), 1615–1619.
112. Schandl, A, Lagergren, J, Johar, A, Lagergren, P, Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer 69 (2016), 43–50.
113. Blazeby, JM, Conroy, T, Hammerlid, E, et al., for the European Organisation for Research and Treatement of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 39 (2003), 1384–1394.
114. Anandavadivelan, P, Lagergren, P, Cachexia in patients with oesophageal cancer. Nat Rev Clin Oncol 13 (2016), 185–198.
115. Heneghan, HM, Zaborowski, A, Fanning, M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg 262 (2015), 803–807.
116. Martin, L, Lagergren, P, Long-term weight change after oesophageal cancer surgery. Br J Surg 96 (2009), 1308–1314.
117. Barlow, R, Price, P, Reid, TD, et al. Prospective multicentre randomised controlled trial of early enteral nutrition for patients undergoing major upper gastrointestinal surgical resection. Clin Nutr 30 (2011), 560–566.
118. Bowrey, DJ, Baker, M, Halliday, V, et al. A randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and feasibility study. Trials, 16, 2015, 531.
119. Dai, Y, Li, C, Xie, Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev, 10, 2014 CD005048.
120. Yang, Z, Wu, Q, Wang, F, Ye, X, Qi, X, Fan, D, A systematic review and meta-analysis of randomized trials and prospective studies comparing covered and bare self-expandable metal stents for the treatment of malignant obstruction in the digestive tract. Int J Med Sci 10 (2013), 825–835.
121. Zhu, HD, Guo, JH, Mao, AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol 15 (2014), 612–619.
122. Wagner, AD, Unverzagt, S, Grothe, W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3, 2010 CD004064.
123. Van Cutsem, E, Moiseyenko, VM, Tjulandin, S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006), 4991–4997.
124. Al-Batran, SE, Hartmann, JT, Probst, S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (2008), 1435–1442.
125. Cunningham, D, Starling, N, Rao, S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med 358 (2008), 36–46.
126. Shah, MA, Janjigian, YY, Stoller, R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol 33 (2015), 3874–3879.
127. Van Cutsem, E, Boni, C, Tabernero, J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 26 (2015), 149–156.
128. Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
129. Ford, HE, Marshall, A, Bridgewater, JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15 (2014), 78–86.
130. Kang, JH, Lee, SI, Lim, DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30 (2012), 1513–1518.
131. Hironaka, S, Ueda, S, Yasui, H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31 (2013), 4438–4444.
132. Fuchs, CS, Tomasek, J, Yong, CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
133. Gaur, P, Hunt, CR, Pandita, TK, Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 7 (2016), 48644–48655.
134. Waddell, T, Chau, I, Cunningham, D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14 (2013), 481–489.
135. Lordick, F, Kang, YK, Chung, HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14 (2013), 490–499.
136. Pearson, A, Smyth, E, Babina, IS, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 6 (2016), 838–851.
137. Murugaesu, N, Wilson, GA, Birkbak, NJ, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 5 (2015), 821–831.
138. Turner, NC, Huang Bartlett, C, Cristofanilli, M, Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373 (2015), 1672–1673.
139. Hortobagyi, GN, Stemmer, SM, Burris, HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375 (2016), 1738–1748.
140. Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (2012), 1382–1392.
141. Swisher, EM, Lin, KK, Oza, AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18 (2017), 75–87.
142. Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
143. Reck, M, Rodriguez-Abreu, D, Robinson, AG, et al., for the KEYNOTE-024 Invesitigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
144. Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
145. Alexandrov, LB, Nik-Zainal, S, Wedge, DC, et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
146. Doi T, Piha-Paul SA, Jalal SI, et al. Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. Gastrointestinal Cancers Symposium; San Fransisco, CA; Jan 21–Jan 23, 2016. 4046.
147. Janjigian, YY, Bendell, JC, Calvo, E, et al. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol, 34(15 suppl), 2016, 4010.
148. Tran, E, Turcotte, S, Gros, A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344 (2014), 641–645.
149. Maude, SL, Frey, N, Shaw, PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
150. Zafar, SY, Currow, DC, Cherny, N, Strasser, F, Fowler, R, Abernethy, AP, Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol 13 (2012), e77–e82.
151. Lee, RT, Ramchandran, K, Sanft, T, Von Roenn, J, Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancerdagger. Ann Oncol 26 (2015), 1838–1845.
152. Davies, AR, Gossage, JA, Zylstra, J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol 32 (2014), 2983–2990.
153. Shapiro, J, van Hagen, P, Lingsma, HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg 260 (2014), 807–813.
154. Haisley, KR, Laird, AE, Nabavizadeh, N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. JAMA Surg, 151, 2016, e162743.
155. van Heijl, M, Sprangers, MA, de Boer, AG, et al. Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol 17 (2010), 23–30.
156. Kidane, B, Sulman, J, Xu, W, et al. Baseline measure of health-related quality of life (functional assessment of cancer therapy-esophagus) is associated with overall survival in patients with esophageal cancer. J Thorac Cardiovasc Surg 151 (2016), 1571–1580.
157. Wikman, A, Johar, A, Lagergren, P, Presence of symptom clusters in surgically treated patients with esophageal cancer: implications for survival. Cancer 120 (2014), 286–293.
158. Benaglia, T, Sharples, LD, Fitzgerald, RC, Lyratzopoulos, G, Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 144 (2013), 62–73.
159. Kumar, S, Huang, J, Abbassi-Ghadi, N, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg 262 (2015), 981–990.